Universal Beteiligungs und Servicegesellschaft mbH Has $15.47 Million Stake in Exelixis, Inc. (NASDAQ:EXEL)

Universal Beteiligungs und Servicegesellschaft mbH raised its holdings in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 16.3% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 419,118 shares of the biotechnology company's stock after buying an additional 58,826 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned 0.15% of Exelixis worth $15,474,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in EXEL. Coppell Advisory Solutions LLC acquired a new stake in Exelixis in the 4th quarter valued at approximately $25,000. Colonial Trust Co SC grew its holdings in Exelixis by 616.9% in the 4th quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company's stock valued at $30,000 after buying an additional 765 shares during the last quarter. Bartlett & CO. Wealth Management LLC bought a new stake in shares of Exelixis in the 1st quarter worth approximately $37,000. Hurley Capital LLC bought a new stake in shares of Exelixis in the 4th quarter worth approximately $68,000. Finally, True Wealth Design LLC lifted its position in shares of Exelixis by 222.3% in the 4th quarter. True Wealth Design LLC now owns 2,253 shares of the biotechnology company's stock worth $75,000 after acquiring an additional 1,554 shares during the period. Institutional investors and hedge funds own 85.27% of the company's stock.

Insider Activity

In other news, Director Stelios Papadopoulos sold 36,508 shares of the company's stock in a transaction that occurred on Thursday, May 15th. The stock was sold at an average price of $44.35, for a total value of $1,619,129.80. Following the transaction, the director owned 1,279,416 shares of the company's stock, valued at approximately $56,742,099.60. This represents a 2.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CMO Amy C. Peterson sold 72,776 shares of the company's stock in a transaction that occurred on Friday, May 16th. The shares were sold at an average price of $45.47, for a total value of $3,309,124.72. Following the completion of the transaction, the chief marketing officer directly owned 465,393 shares in the company, valued at $21,161,419.71. The trade was a 13.52% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 458,113 shares of company stock valued at $21,024,817. 2.85% of the stock is owned by insiders.

Exelixis Price Performance

NASDAQ EXEL traded down $1.16 during trading on Monday, reaching $44.44. 1,442,737 shares of the company's stock were exchanged, compared to its average volume of 2,917,193. The business has a 50 day moving average price of $43.46 and a 200-day moving average price of $38.85. The stock has a market capitalization of $12.12 billion, a P/E ratio of 20.24, a PEG ratio of 0.91 and a beta of 0.28. Exelixis, Inc. has a fifty-two week low of $22.96 and a fifty-two week high of $49.62.

Analyst Ratings Changes

A number of analysts have commented on the company. HC Wainwright raised their price objective on Exelixis from $47.00 to $53.00 and gave the stock a "buy" rating in a research report on Monday, June 30th. Stephens upgraded Exelixis from an "equal weight" rating to an "overweight" rating and raised their price objective for the stock from $29.00 to $60.00 in a research report on Tuesday, June 24th. Citigroup raised their target price on Exelixis from $45.00 to $56.00 and gave the stock a "buy" rating in a research report on Thursday, May 15th. Guggenheim set a $45.00 target price on Exelixis and gave the stock a "buy" rating in a research report on Thursday, May 15th. Finally, Benchmark restated a "neutral" rating on shares of Exelixis in a research report on Monday, June 23rd. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $45.33.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.